NxThera said today that health insurers Humana and Aetna will now provide coverage for its Rezūm system designed for the minimally invasive treatment of benign prostatic hyperplasia, or enlarged prostate.
NxThera’s Rezūm system is designed to use radiofrequency current to create thermal energy to ablate obstructive prostate tissue which causes BPH through targeted treatments.
The Maple Grove, Minn.-based company said that with the additional reimbursement win, its Rezūm system is now available to more than 80% of men with BPH in the US.
“Our mission is to improve the lives of men suffering from BPH, and the Rezūm System provides urologists and their patients with a safe, effective and durable treatment option with minimal discomfort. The recently published 2-year data from our Rezūm II pivotal study demonstrates sustained and durable symptom relief and preserved sexual function in patients who were treated with the Rezūm System. These compelling clinical outcomes from a minimally invasive procedure that can be performed in an office or outpatient setting, provide an efficient and cost-effective BPH treatment option for urologists, patients and health plans,” CEO Bob Paulson said in a prepared statement.
Last month, NxThera raised $14.6 million in a new round of debt financing, according to an SEC filing. The company offered convertible promissory notes and Series C preferred stock warrants in the round, according to the filing, with the 1st sale noted on Jan. 13.